A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis
A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis
The purpose of this study is to learn more about the role of etanercept alone or in combination with methotrexate on disease activity in adults with psoriatic arthritis.
The study will consist of a 30-day screening period, a 48-week double-blind treatment period and a 30-day safety follow-up period.
At or after week 24, participants with an inadequate response could receive rescue therapy with etanercept plus methotrexate until the end of the treatment period.
Key Inclusion Criteria:
Exclusion Criteria:
Ciudad Autonoma de Buenos Aires, Buenos Aires C1015ABO, Argentina
Ostrava-Trebovice, 722 00, Czechia
Lyon Cédex 3, 69437, France
Mexicalli, Baja California Norte 21200, Mexico
Panorama, Western Cape 7500, South Africa